Fibroblast growth factor receptor

Tyra Biosciences to Present at Upcoming Investor Conferences

Retrieved on: 
Tuesday, February 27, 2024
FGFR, Fibroblast growth factor receptor, Barclays, Biology, Conference, Pharmaceutical industry

TYRA management will also participate in one-on-one meetings with investors during the conference.

Key Points: 
  • TYRA management will also participate in one-on-one meetings with investors during the conference.
  • Jefferies Biotech On the Bay Summit, March 11-13th: TYRA management will participate in one-on-one meetings with investors during the conference.
  • TYRA management will also participate in one-on-one meetings with investors during the conference.
  • A live and archived webcast of the Cowen presentation and Barclays fireside chat will be available via the For Investors page on the Investor section of the TYRA website.

Tyra Biosciences to Present at Oppenheimer's 34th Annual Healthcare Life Sciences Conference

Retrieved on: 
Wednesday, February 7, 2024
Biology, Fibroblast growth factor receptor, FGFR, Conference

CARLSBAD, Calif., Feb. 7, 2024 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today announced that Todd Harris, CEO of TYRA, will present at Oppenheimer's 34th Annual Healthcare Life Sciences Conference on Tuesday, February 13, 2024, at 2pm ET.

Key Points: 
  • CARLSBAD, Calif., Feb. 7, 2024 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today announced that Todd Harris, CEO of TYRA, will present at Oppenheimer's 34th Annual Healthcare Life Sciences Conference on Tuesday, February 13, 2024, at 2pm ET.
  • The conference is being held in a virtual format.
  • A live and archived webcast of the presentation will be available via the For Investors page on the Investor section of the TYRA website.

Onconova Therapeutics’ Preclinical Narazaciclib Data at SABCS Highlights Differentiated Anti-Tumor Activity v. Other CDK4/6i’s

Retrieved on: 
Friday, December 8, 2023
BUB1, Breast cancer, Immortalised cell line, Autophagy, FDA, Breast, Therapy, CXCL10, Cancer, Observation, Growth, Patient, Fibroblast growth factor receptor, Pharmaceutical industry

NEWTOWN, Pa., Dec. 08, 2023 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova” or “the Company”), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced preclinical data highlighting narazaciclib’s multi-kinase profile, broad anti-tumor activity and increased anti-tumor immunity, compared to palbociclib and other CDK4/6 inhibitors, in a poster presented at the San Antonio Breast Cancer Symposium (SABCS) on December 8, 2023.

Key Points: 
  • In addition, narazaciclib treatment induced higher levels of T-cell recruiting chemokines, supporting greater anti-tumor immune activity.”
    “We believe that the totality of the data presented at SABCS supports narazaciclib’s multi-kinase activity, its ability to target resistance pathways missed by other CDK4/6 inhibitors, and its differentiated anti-tumor and immunomodulatory activity.
  • Objectives: To explore the activity of narazaciclib and its metabolite, ON1232580, in comparison to the FDA-approved CDK4/6 inhibitor (CDK4/6i) palbociclib, and identify additional targets engaged by narazaciclib.
  • These data support the potential use of narazaciclib in breast cancer and UCEC, either as monotherapy or in combination with other agents.
  • These results suggest that narazaciclib has the differentiated potential to promote greater levels of anti-tumor immunity, which could enhance its efficacy.

Tyra Biosciences to Participate in 2023 Jefferies London Healthcare Conference

Retrieved on: 
Wednesday, November 8, 2023
FGFR, Conference, Fibroblast growth factor receptor, Biology, Pharmaceutical industry

CARLSBAD, Calif., Nov. 8, 2023 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today announced that management will participate in the 2023 Jefferies London Healthcare Conference, taking place November 14-16, 2023.

Key Points: 
  • CARLSBAD, Calif., Nov. 8, 2023 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today announced that management will participate in the 2023 Jefferies London Healthcare Conference, taking place November 14-16, 2023.
  • Todd Harris, CEO of TYRA, will participate in a fireside chat on Tuesday, November 14, 2023, at 1:30 pm GMT.
  • A live and archived webcast of the fireside chat will be available via the For Investors page on the Investor section of the TYRA website.

Tyra Biosciences Announces Oral Presentations on TYRA-300 for Achondroplasia at the ASBMR and ASHG 2023 Annual Meetings

Retrieved on: 
Thursday, September 21, 2023
FGFR, American Society for Bone and Mineral Research, ASHG, American Society of Human Genetics, Achondroplasia, Human genetics, Biology, Fibroblast growth factor receptor, Society, Pharmaceutical industry

CARLSBAD, Calif., Sept. 21, 2023 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today announced that TYRA will deliver oral presentations on TYRA-300 for achondroplasia at the American Society for Bone and Mineral Research (ASBMR) and the American Society of Human Genetics (ASHG) 2023 annual meetings.

Key Points: 
  • CARLSBAD, Calif., Sept. 21, 2023 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today announced that TYRA will deliver oral presentations on TYRA-300 for achondroplasia at the American Society for Bone and Mineral Research (ASBMR) and the American Society of Human Genetics (ASHG) 2023 annual meetings.
  • ASBMR is taking place October 13-16, 2023, in Vancouver, BC, Canada and ASHG is taking place November 1-5, 2023, in Washington, DC.
  • More information on the annual meetings can be found below:

Tyra Biosciences Announces FDA Orphan Drug Designation for TYRA-300 for the Treatment of Achondroplasia

Retrieved on: 
Tuesday, August 1, 2023
Osteochondrodysplasia, FGFR3, FGFR, Achondroplasia, Medical Affairs Bureau, ODD, Quality of life, Mutation, Sleep apnea, Hydrocephalus, Dwarfism, Biology, Diagnosis, Hospital, Rare, FDA, Fibroblast growth factor receptor, Nemours Children's Hospital, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, IND, Food, Spinal stenosis, Pharmaceutical industry, Medical device

People living with achondroplasia may experience severe skeletal complications including cranial and spinal stenosis, hydrocephalus and sleep apnea.

Key Points: 
  • People living with achondroplasia may experience severe skeletal complications including cranial and spinal stenosis, hydrocephalus and sleep apnea.
  • TYRA-300 is an oral FGFR3 selective inhibitor whose design may have a meaningful impact on achondroplasia and other skeletal dysplasias.
  • "People living with achondroplasia can have significant health complications that are not adequately addressed with currently available therapies.
  • "The FDA's decision to grant Orphan Drug Designation to TYRA-300 is an important recognition of the potential of our approach to deliver benefit to the achondroplasia community.

Zai Lab Announces First Patient Treated in Mainland China for the Global Phase 3 FORTITUDE-101 Study of Bemarituzumab in First-Line Gastric Cancer

Retrieved on: 
Friday, July 14, 2023
Amgen, Partnership, Fibroblast growth factor receptor, HKEX, Patient, GEJ, Therapy, Stomach, FC, Nivolumab, Pharmaceutical industry

FORTITUDE-101 is a global trial of bemarituzumab in first-line gastric cancer sponsored by Amgen.

Key Points: 
  • FORTITUDE-101 is a global trial of bemarituzumab in first-line gastric cancer sponsored by Amgen.
  • Adult patients with FGFR2b overexpression will be randomized to bemarituzumab plus chemotherapy (mFOLFOX6), versus placebo plus chemotherapy (mFOLFOX6).
  • In early 2024, Zai Lab will join the Amgen-sponsored global Phase 3 FORTITUDE-102 study in first-line gastric cancer.
  • This study is evaluating bemarituzumab plus chemotherapy and nivolumab, versus placebo plus chemotherapy and nivolumab for untreated advanced gastric and GEJ cancer with FGFR2b overexpression.

Tyra Biosciences to Participate in Upcoming Investor Conferences

Retrieved on: 
Wednesday, March 29, 2023
FGFR, Biology, Bank, Fibroblast growth factor receptor, Pharmaceutical industry

CARLSBAD, Calif., March 29, 2023 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today announced that management will present and participate in the following investor conferences:

Key Points: 
  • CARLSBAD, Calif., March 29, 2023 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today announced that management will present and participate in the following investor conferences:
    Todd Harris, CEO of TYRA, will participate virtually in a fireside chat on Tuesday, April 4, 2023, at 2:15 pm ET
    Mr. Harris will present on Thursday, May 11, 2023, at 9:35 am PT
    A live and archived webcast of the Bank of America event will be available via the For Investors page on the Investor section of the TYRA website.

Allarity Therapeutics Provides Updates for IXEMPRA and Stenoparib Phase 2 Monotherapy Clinical Studies

Retrieved on: 
Tuesday, March 28, 2023
SAB, DRP, Therapy, Clinical trial, COVID, BID, Fibroblast growth factor receptor, Ovarian cancer, ChromeOS, Allar language, Pharmaceutical industry

BOSTON — March 28, 2023 – Allarity Therapeutics, Inc. (NASDAQ: ALLR) (“Allarity” or “the Company”), a clinical-stage pharmaceutical company developing novel oncology therapeutics together with drug-specific DRP® companion diagnostics for personalized cancer care, today announced updates to its ongoing phase 2 clinical programs evaluating IXEMPRA® and stenoparib as monotherapies.

Key Points: 
  • BOSTON — March 28, 2023 – Allarity Therapeutics, Inc. (NASDAQ: ALLR) (“Allarity” or “the Company”), a clinical-stage pharmaceutical company developing novel oncology therapeutics together with drug-specific DRP® companion diagnostics for personalized cancer care, today announced updates to its ongoing phase 2 clinical programs evaluating IXEMPRA® and stenoparib as monotherapies.
  • For both IXEMPRA and stenoparib monotherapy trials, Allarity is taking steps to accelerate patient recruitment to support the goals for interim data readouts by the end of 2023.
  • The Company has also made changes to the clinical trial protocols to increase the availability of eligible participants for both monotherapy studies.
  • The Company is also evaluating stenoparib as a monotherapy in ovarian cancer in an ongoing DRP-guided Phase 2 clinical trial.

Allarity Therapeutics Doses First Patient in Phase 1b Clinical Trial Evaluating Dovitinib and Stenoparib Combination in Advanced Solid Tumors

Retrieved on: 
Monday, March 20, 2023
DNA, Index, MOA, Therapy, Neoplasm, Poly (ADP-ribose) polymerase, Nutrient, Coronavirus Scientific Advisory Board, Gynecologic Oncology (journal), Moa, Associate, MS, Blood, Downregulation and upregulation, Patient, Mass, Clinical research, HR, MTD, Growth, Fibroblast growth factor receptor, Principal, Ovarian cancer, Death, PARP, PTK, Homologous recombination, Safety, Pharmaceutical industry, Medical imaging, MD

“Having investigated novel combinations of anticancer agents, including a PARP inhibitor and an anti-angiogenic therapeutic, we have seen improved efficacy.

Key Points: 
  • “Having investigated novel combinations of anticancer agents, including a PARP inhibitor and an anti-angiogenic therapeutic, we have seen improved efficacy.
  • The Phase 1b trial is designed with a target enrollment of up to 36 patients with advanced solid tumors, focusing on specific tumor types that Allarity anticipates will be most responsive to the drug combination.
  • Researchers will analyze patient tumor samples retrospectively using Allarity’s DRP® companion diagnostics for stenoparib and dovitinib.
  • Allarity holds exclusive, global commercial rights to both dovitinib and stenoparib.